<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://pharmoniq.com/news/sellas-gps-vaccine-phase-3-regal-aml-survival</loc>
    <news:news>
      <news:publication>
        <news:name>PharmoniQ</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T07:58:08.101Z</news:publication_date>
      <news:title>SELLAS Vaccine Cuts Death Risk 41% in Phase 3 Leukemia Trial</news:title>
      <news:keywords>SELLAS Life Sciences, acute myeloid leukemia, cancer vaccine, phase 3, clinical trials</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pharmoniq.com/news/lilly-15th-buyout-2026-calytrix-bio-up-to-1-5b</loc>
    <news:news>
      <news:publication>
        <news:name>PharmoniQ</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T13:59:47.913Z</news:publication_date>
      <news:title>Lilly&apos;s 15th Buyout of 2026 Is Up to $1.5B for Blood Cancer Startup</news:title>
      <news:keywords>Eli Lilly, Calytrix Bio, acquisitions, myelofibrosis, antibodies</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pharmoniq.com/news/fda-approves-roche-wilserdly-giredestrant-esr1-breast-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>PharmoniQ</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T08:04:04.965Z</news:publication_date>
      <news:title>FDA Approves Roche Pill After 62% Cut in Progression or Death Risk</news:title>
      <news:keywords>Roche, Genentech, breast cancer, FDA approval, oncology</news:keywords>
    </news:news>
  </url>
</urlset>